A global biopharmaceutical company, AbbVie develops and sells medicines for immune, nerve, and cancer conditions — brands include Skyrizi, Rinvoq, Humira, Botox, and Imbruvica — as well as cosmetic treatments like Botox Cosmetic and the Juvederm line. It was born in 2013 when Abbott Laboratories split, spinning off its drug business into a fresh company. Fun fact: the name blends "Abb" (from Abbott) with "Vie," echoing the Latin word for "life," and insiders noted it conveniently rhymes with "R&D."
Q2 2026 net income rose 285% to $3.6B as no contingent charge hit the quarter
No contingent consideration charge hit the quarter, unlike the prior four. rose 10.2% to $17.0B and rose 290% to $2.03 as widened 2.9 points to 74.7% on product mix and lower . The underlying and Rinvoq growth story held, but the next revaluation remains the swing factor.
Key takeaways
rose 285.2% to $3,613M and rose 290.4% to $2.03, with no non-cash contingent consideration charge recorded after $2.4B hit Q1 2026 and $2.8B hit Q2 2025.
rose 10.2% to $17.0B and 13.3% sequentially to $17.0B, continuing the and Rinvoq-led growth that has offset biosimilar erosion since 2024.
widened 2.9 points to 74.7% and widened 6.1 points to 37.9%, helped by , lower , and favorable product mix.
Section summaries
Legal Proceedings
AbbVie is party to antitrust, product liability, and intellectual property litigation; it believes no matter will materially harm its financial position.
⌄
Litigation accruals totaled approximately $1.7 billion as of June 30, 2026, up from $1.6 billion at year-end 2025.
Antitrust cases over a 2005 Niaspan patent settlement include a certified direct-purchaser class action and a California state suit seeking restitution and penalties.
fell 33.3% to $3,436M and fell 36.2% to $3,114M , down from the Q2 2025 working-capital recovery base.
Litigation accruals totaled $1.7B as of June 30, 2026, and AbbVie agreed in June 2026 to resolve substantially all U.S. Biocell textured breast implant ALCL suits, with about 2,855 other such suits remaining.
What changed
Q2 2026 combined and Rinvoq sustained growth as flagged; the quarter carried no contingent charge after Q1 2026's $2.4B and FY2025's $6.5B tied to Skyrizi estimates.
narrowed to $5.9B from $6.6B in Q1 2026, after the FY2025 deficit of $3.2B formed as dividends exceeded .
was $1.7B at June 30, 2026 versus $1.6B at year-end 2025 and $1.7B in Q1 2026; Allergan opioid suits numbered about 320 in Q1 and the Biocell count is now ~2,855 remaining after June resolution.
did not recover toward 2022 levels; Q2 2026 was $3,436M, down 33.3% , versus the $24.9B full-year 2022 figure flagged in prior filings.
Imbruvica government-set Medicare price effective 2026 was flagged as a FY2025 watch item; the Q2 2026 filing does not report a separate Imbruvica impact figure.
What to watch
Next contingent consideration revaluation after the $2.4B Q1 2026 charge tied to sales estimates
Q3 2026 combined and Rinvoq as erosion continues from the Q1 40% constant-currency decline
Movement in the $1.7B and remaining Biocell (~2,855) and Allergan opioid (~320) suits
First outlay or financial impact from the $100B January 2026 voluntary U.S. agreement and the Imbruvica Medicare price
In June 2026, AbbVie agreed to resolve substantially all U.S. lawsuits alleging Biocell textured breast implants caused ALCL; about 2,855 other suits remain in U.S. and foreign courts.
A alleges 's list price is excessive; the case was in January 2026 and the plaintiff appealed in March 2026.
AbbVie is enforcing patents for and against multiple generic filers, seeking .